



# EUROGIN 2015

## HPV Infection and Related Cancers: Translating Research Innovations into Improved Practice

Sevilla, Spain

February 4-7, 2015

Advanced Program  
(subject to change)

**Wednesday, Feb. 4**

### Main Training Course (MTC)

The main training course is designed to provide summaries of the most relevant knowledge on HPV infection and associated diseases with the aim of assisting physicians and educators. The topics covered range from the basic science fundamentals to emerging issues and the clinical uses of screening technologies, prophylactic HPV vaccines and extending to HPV-related diseases in external genitalia and head & neck.

Speakers will present only accepted evidence-based scientific information that has been published in the peer-reviewed medical literature.

9:00 - 10:30		MTC1 - From infection to diseases at different anatomic sites				Main auditorium			
Chairs : S. Franceschi									
• HPV related cancers: the comparative figures		Franceschi	S.	France					
• Epidemiology, transmission & natural history		Lu	B.	USA					
• The biology of HPV infection at different epithelial sites		Doorbar	J.	UK					
• HPV immunology: an update		Wu	TC	USA					
• Discussion									

11:00 - 12:45		MTC 2 - New strategies & innovations in cervical cancer control				Main auditorium			
Chairs : X. Bosch									
• New standards for HPV-based cervical cancer screening		Franco	E.	Canada					
• HPV prophylactic vaccines: lessons learned from 10 years experiences		Brotherton	J.	Australia					
• Integrating primary & secondary prevention: new strategies for cervical cancer control LIC vs HIC		Gravitt	P.	USA					
• Challenges facing novel HPV multivalent vaccine		Joura	E.	Austria					
• The expectancy of HPV therapeutic vaccine		Stanley	M.	UK					
• Discussion									

9:00 -	<b>OC 1 - HPV testing 1</b>	Auditorium 3		
10:30	<b>Chairs : C. Clavel - J.P Bogers*</b>			

11:00 -	<b>OC 2 - Epidemiology &amp; natural history 1</b>	Auditorium 3		
12:45	<b>Chairs : I Baussano - G. Ogilvie*</b>			

14:30 -	<b>MTC 3 - Management of HPV cervical diseases - the state of the art</b>	Main auditorium		
16:00	<b>Chairs : W. Kinney</b>			
	• The risk-based management	Stoler	M.	USA
	• Triage options of HPV+ women	Meijer	C.	Netherlands
	• Triage strategies of abnormal cytology	Kinney	W.	USA
	• Post-treatment surveillance options	Arbyn	M.	Belgium

16:30 -	<b>MTC 4 - HPV-associated diseases in non-cervical sites - what the clinician should know</b>	Main auditorium		
18:00	<b>Chairs : A. Giuliano - M. Gillison</b>			
	• Comparative epidemiology and HPV transmission by gender	Giuliano	A.	USA
	• Current developments on HPV-caused oropharyngeal cancer	Gillison	M.	USA
	• Clinical issues related to anal HPV infection and cancer	Fairley	C.	Australia
	• HPV-associated OPC cancer, the state of the art	Brakenhoff	R.	Netherlands
	• The potential of HPV prophylactic & therapeutic vaccines	Brisson	M.	Canada

14:15 -	<b>OC 3 - Vaccine 1 (Impact)</b>	Auditorium 3		
16:00	<b>Chairs : K. Sundström - K. Soldan</b>			

16:30 -	<b>OC 4 - Vaccine 2 (Effectiveness &amp; safety)</b>	Auditorium 3		
18:30	<b>Chairs : M. Lehtinen* - K. Canfell*</b>			

Wednesday, Feb. 4

**WACC Forum & health education**  
**Benefits and limitations of increasingly informed patients**

The WACC Forum (February 4) is organized by the Women Against Cervical Cancer (WACC) Network which represents more than 50 associations from many different countries working for the benefit of womens' health and involved in cervical cancer prevention.

This conference gathers players in the public health education sector from a number of countries, to share experiences on effective communication and learning tools aimed to increase HPV disease awareness and patient education towards active prevention.

10:00 - 13:00	<b>WACC 1 - Anti-vaccine movements: tactics and solutions</b>	Madrid			
	<b>Chairs : M. Steben</b>				
	<b>Lecture:</b> The science facts about adverse events & HPV vaccines	Garland	S.	Australia	
	• Understanding the tricks and tropes of the antivaccinologists	Steben	M.	Canada	
	• Crisis management: do we need to answer all attacks of antivaccinologists?	Bravo	E.	Spain	
	• Are all experts banned from sharing their knowledge because of collaboration with the industry?	Meijer	C.	Netherlands	
	• Composition of expert teams involved in health technology assessment and decision-making in the field of cervical cancer prevention and potential conflict of interest - the example of Belgium	Arbyn	M.	Belgium	
	• Research on attitudes and acceptance of HPV vaccine	Waller	J.	UK	
	• Helping community groups in their communication activities	Smith	J.	USA	
	• Questions and comments from the audience				

14:30 -	<b>WACC 2 - Patient survivors' voices: what they want?</b>				
16:00	<b>Chairs : J. Smith</b>	Madrid			
	• Information : transmission, risk of cancer, protection				
	- Cervical cancer	Gravitt	P.	USA	
	- Anal cancer	Bower	M.	UK	
	- Oropharyngeal cancer	Fakhry	C.	USA	
	• The interface between science and policy for global cervical cancer control?	Qiao	YL	China	
	• Print media coverage of the link between HPV and oral cancer in the UK	Waller	J.	UK	
	• Current knowledge about the diseases and best standard of care	Smith	J.	USA	
	• End with the disparity	Ogilvie	G.	Canada	
	• HPV vaccination in Europe: multidisciplinary approach: gynecologist, pediatricians, GP's, Public Health providers	Martinon-Torres	F.	Spain	

	<b>OC 5 - WACC (proffered papers)</b>				
16:30 -					
18:30	<b>Chairs : F. Martinon-Torres - M. Pitts - J. Waller</b>	Madrid			

## EUROGIN 2015 - Jornada Española y Spanish Session

EUROGIN ha convocado su Reunión 2015 en Sevilla, España, a celebrar entre los días 4 y 7 de Febrero de 2015. EUROGIN, como es su norma, ofrece un ámbito académico de conocimiento y discusión de toda la información actualizada sobre el mundo del virus del papiloma humano (VPH). Ahora mismo el reto que afrontamos es llevar a la práctica clínica diaria todas las modificaciones de recomendaciones y conductas sustentadas en la evidencia de alta calidad obtenida en los últimos años: el título de la Reunión de Sevilla así lo anuncia: "*HPV Infection and Related Cancers: Translating Research Innovations into Improved Practice*".

Para cubrir este objetivo todas las últimas novedades van a ser presentadas y debatidas desde una óptica multidisciplinar, aspecto imprescindible para un correcto abordaje de los problemas y sus soluciones. Todas las especialidades concernidas por la patología VPH han sido convocadas, ginecólogos y pediatras, generalistas y epidemiólogos, otorrinolaringólogos y expertos en Salud Pública, virólogos y patólogos. Os esperamos en Sevilla para aprender todos juntos, mejorar nuestra práctica clínica y proteger mejor la salud de nuestra población.

El Programa de la Reunión incluye una Jornada Española y una *Spanish Session*, así como el anuncio de una importante reducción de la cuota de inscripción para los médicos españoles, que contarán también con la posibilidad de inscribirse únicamente a la "Jornada Española".

### Wednesday, Feb. 4

#### Mañana

9:30 -	<b>SW 1 - Curso de Colposcopia</b>	Auditorium 2			
11:15					
	<b>Director: JC Martínez Escoriza</b>				
	• Imágenes Normales	Dexeus	D.		
	• Imágenes Anormales	Coloma	F.		
	• La colposcopia en el contexto de los modelos de cribado actuales	Cararach	M.		
	• Análisis crítico de la Clasificación Colposcópica de Rio de Janeiro 2012	Martínez Escoriza	J.C.		
	• Casos Clínicos	Martínez Escoriza	J.C.		
		Montserrat	J.A.		

11:15 -	<b>SW 2 - Verrugas Genitales/Cribado/Consenso</b>	Madrid			
13:00					
	• Verrugas Genitales: Estudio Multicéntrico Español	de la Fuente	J.		
	• Situación de la Prevención Primaria del Cáncer de Cuello de Útero en España: Fases IV.	Brotos	M.		
	• Presentación del Documento de Consenso de Prevención del Cáncer de Cuello de Útero en España 2014: Consenso SEGO-AEPPC-SEAP-SEC.	Torné	A.		
	• Debate				

## Tarde

14:30 - 16:25	<b>SW 3 - Equidad asistencial: de la oncoguía a la practica clínica</b>	Auditorium 2			
	<b>Moderador: J. Ponce</b>				
	• Epidemiología en España de los tumores del Tracto Genital Inferior VPH relacionados	Bruni	L.		
	• Estrategia y metodología del programa OncoGuías SEGO 2008-2016	Cusidó	M.		
	• OncoGuía Prevención Secundaria del Cáncer de Cuello de Útero	del Pino	M.		
	• OncoGuía Cáncer Invasor de Cuello de Útero 2013	Martí	L.		
	• Caso clínico interactivo: Cáncer de Cuello de Útero	Domingo	S.		
	• OncoGuía Cáncer Escamoso Invasor de Vulva 2015	Lombardía	J.		
	• Caso clínico interactivo: Cáncer de Vulva	Chiva	L.		

17:00 - 18:00	<b>SW 4 - Técnica quirúrgica en el cáncer de cuello uterino</b>	Auditorium 2			
	<b>Moderador: A. Sánchez del Rio</b>				
	• Histerectomía Radical. Anatomía quirúrgica (video)	Muruzábal	J.C.		
	• Linfadenectomía pélvica y ganglio centinela (video)	Gil	A.		
	• Linfadenectomía aorto-cava pre y transperitoneal (video)	Barahona	M.		
	• Efectividad de la robótica en España. Encuesta Nacional ROBOCER 2014	Ponce	J.		

18:00 - 19:00	<b>SW 5 - La educación en el médico de cabecera en el VPH</b>	Auditorium 2			
	<b>Moderadoras: E. Redondo &amp; I. Jimeno</b>				
	En colaboración con SEMERGEN, SEMG				
	• La Educación en VPH del Médico Generalista	Alonso	J.		
	• El papel del Médico Generalista en la Prevención Primaria y Secundaria del Cáncer de Cérvix	Cano	A.		

Thursday, Feb. 5

Main Scientific Sessions include keynote lectures providing a broad overview of the essential issues on cervical cancer prevention by the most prominent experts in their respective field.

8:15 - 9:45	<b>MSS1 - How to introduce HPV testing into primary screening?</b>	Main auditorium			
	<b>Chairs : J. Dillner - H. Lawson</b>				
	• Do the current criteria for the recommendation of new HPV tests for cervical cancer screening need to be refined ?	Iftner	T.	Germany	
	• Cotesting vs primary standalone HPV testing	Lawson	H.	USA	
	• What test to use, is genotyping important?	Cuzick	J.	UK	
	• Ages for HPV screening: when to start, when to stop?	Franco	E.	Canada	
	• What to do if HPV negative? Interval of screening	Dillner	J.	Sweden	
	• Impact of vaccination on primary HPV screening	Bosch	X.	Spain	
	• Discussion				

9:45 - 11:30	<b>MSS 2 - Surveillance and impact of HPV prophylactic vaccines in population: current picture</b>	Main auditorium			
	<b>Chairs : J. Brotherton - P.L. Lopalco</b>				
	• Vaccine uptake accross the world	Bloem	P.	Switzerland	
	• Monitoring impact in population	Soldan	K.	UK	
	• Post-vaccination HPV infection surveillance	Castellsagué	X.	Spain	
	• Changes in disease prevalence in vaccinated women				
	- Genital warts	Arnheim-Dahlström	L.	Sweden	
	- Cervical diseases	Brotherton	J.	Australia	
	• Cancer registries: up to the task of monitoring post vaccination reductions in HPV-related cancers?	Bray	F.	France	
	• Monitoring of RRP in the post vaccine era	Campisi	P.	Canada	
	• Long-term efficacy of HPV vaccination against hard endpoints	Paavonen	J.	Finland	

8:15 -	<b>OC 6 - Vaccine 3 (New developments)</b>	Auditorium 3			
9:45	<b>Chairs : P. Bonanni* - E. Joura</b>				

### Clinical Sessions (CS)

The clinical sessions are designed to provide educational strategies and skill-building learning experiences and update of expertise for participants. The clinical sessions should enable participants to integrate in their everyday practice the basic and advanced principles of colposcopy as well as diagnosis and management of cervico-vaginal and vulvar diseases.

8:30 -	<b>CS 1 - Clinical advances &amp; modern management of vulvar carcinoma</b>	Auditorium 2			
10:00	<b>Chairs : C. Haie-Meder - M. Roy</b>				
	• Current knowledge on burden, epidemiology & carcinogenesis	Tristram	A.	UK	20
	• The contribution of sentinel lymph node detection & new development in vulvar cancer surgery	van der Zee	A.	Netherlands	30
	• What remains of radiotherapy indications?	Haie-Meder	C.	France	20

10:00 -	<b>CS 2 - HPV infection &amp; precancers of the vulva</b>	Auditorium 2			
11:30	<b>Chairs : A. Fiander - J. Bornstein</b>				
	• Terminology	Bornstein	J.	Israel	
	• Epidemiology of HPV infection	Goodman	M.	USA	
	• Diagnosis	Roy	M.	Canada	
	• Treatment - Management	Tristram	A.	UK	
	• Immunotherapy	Van Esch	E.	Netherlands	

8:30 -	<b>OC 7 - H&amp; N Oral Communications</b>	Madrid			
10:00	<b>Chairs : S. Syrjänen - M. Quer - H. Mirghani</b>				

10:00 -	<b>OC 8 - H&amp; N Oral Communications</b>	Madrid			
11:30	<b>Chairs : B. Burtneess - L. Licitra</b>				



The colposcopy course is an intensive course conducted by 2 highly experienced colposcopists/oncologists. They will present the most up-to-date knowledge relating to colposcopy practice as well as of the management of the cervix and lower genital tract precancer. There will be lectures as well as a very informal interactive tutorial which will be clinically oriented. Topics will range from the basic (i.e. normal cervix) to advanced (i.e. micro-invasion and glandular disease). A CD (PDF format) of all PowerPoint lectures will be given out.

7:30 - 11:30	<b>Colposcopy course</b>	Bruselas			
	<b>Chairs : A. Singer - N. Pisal</b>				
7:30	• Registration				
8:00	• The normal cervix				
8:20	• New ideas on CIN and cervical glandular disease and their detection - use of cytology +/- HPV				
9:10	• Discussion				
9:20	• The abnormal cervix - the use of colposcopy (including video presentations)				
10:10	• Discussion				
10:20	• Coffee and cakes				
10:30	• Why, who, how to treat CIN/glandular disease				
11:10	• Interactive case presentation				
11:30	• Summary and close				

14:45 -	<b>MSS 3 - Funding cervical cancer control</b>	Main auditorium			
16:00	<b>Chairs : E. Franco</b>				
	• Being victims of our own success: funding decreases for cervical cancer control	Franco	E.	Canada	
	• The agenda agencies and charity organizations				
	- NIH	Wiesch	D.	USA	
	- PATH	LaMontagne	S.	USA	
	• What do financial cuts in health care systems means for cervical cancer prevention in Europe?	Bosch	X.	Spain	

16:30 -	<b>MSS 4 - Methods of triage of HPV+ women</b>	Main auditorium			
18:00	<b>Chairs : C. Meijer, A. Lorincz</b>				
	• Cytology	Dillner	J.	Sweden	
	• Host methylation	Meijer	C.	Netherlands	
	• Viral methylation and p16 mRNA test	Lorincz	A.	UK	
	• p16	Wentzensen	N.	USA	
	• Combination strategies	Stoler	M.	USA	

### Scientific Session (SS)

The concurrent scientific sessions feature presentations of selected abstracts on new findings covering a broad range of topics related to genital cancer prevention and management of patients with HPV-associated diseases.

14:45 -	<b>SS 1 - Immunotherapy of HPV-associated diseases</b>	Auditorium 3			
16:15	<b>Chair : M. Stanley - P. Stern</b>				
	• Development of immune checkpoint inhibitors for SCCHN therapy	Melillo	G.	USA	
	• Optimization and development of a therapeutic anti-HPV vaccine in Ear, Nose, Throat (ENT) cancer	Badoual	C.	France	
	• Protease inhibitor in treatment of CIN	Hampson	I.	UK	

16:30 - 18:00	<b>SS 2 - New challenges facing HPV 16 &amp; 18 infection</b>	Auditorium 3			
	<b>Chair : X. Bosch</b>				
	• HPV 16 & 18 prevalence and burden of associated cancers	Clifford	G.	France	
	• Assessing cancer risk of HPV 16 & 18 infection	Franco	E.	Canada	
	• Immune responses, regression and persistence of HPV 16 & 18	Mosciki	AB	USA	
	• Immune responses to HPV therapeutic vaccines	Wu	TC	USA	
	• ProCervix, a new vaccine for HPV 16 & 18 infected women prior to development of high-grade cervical lesions: from Phase I to Phase II.	Van Damme	P.	Belgium	
	• New paradigms of HPV 16& 18 associated cancer control, the respective role of prevention, screening and immunotherapy	Brisson	M.	Canada	
14:45 - 16:15	<b>CS 3 - ADC in situ and invasive adenocarcinoma of the cervix: an update</b>	Auditorium 2			
	<b>Chairs : K. Ault</b>				
	• Current worldwide figure	Ault	K.	USA	
	• Human papillomavirus types in glandular lesions of the cervix: A meta-analysis of published studies	Clifford	G.	France	
	• Molecular approaches	Doorbar	J.	UK	
	• Overview of relevant immunological factors for adenocarcinoma of cervix	Stern	P.	UK	
	• Cervical screening and adenocarcinoma: Impact of cytology based screening and likely impact of HPV testing	Sasieni	P.	UK	
	• HPV prophylactic vaccine efficacy & impact	Brown	D.	USA	
16:30 - 18:00	<b>CS 4 - The new face of colposcopy at the age of technical progress</b>	Auditorium 2			
	<b>Chairs : W. Prendiville - P. Hillemanns</b>				
	• Colposcopy e-training	Singer	A.	UK	
	• Colposcopic performance & utility today	Dexeus	S.	Spain	
	• Indications of colposcopy based on HPV screening	Huh	W.	USA	
	• New biometric diagnostic	Prendiville	W.	Ireland	
18:00 - 19:15	<b>OC 9 - Colposcopy - Management</b>	Auditorium 2			
	<b>Chairs : E. Siegler - K. Elfgren</b>				
14:45 - 16:00	<b>OC 10 - HPV testing 2</b>	Madrid			
	<b>Chairs : H. Cubie - J.L. Pr��tet</b>				
16:30 - 18:00	<b>OC 11- Epidemiology &amp; natural history 2</b>	Madrid			
	<b>Chairs : P. Sparen - H. Ikenberg</b>				

## Friday, Feb. 6

8:30 - 10:00	<b>MSS 5 - Moving from cyto to HPV-based primary screening - Mutualizing experiences / implementation issues</b>	Auditorium 3			
	<b>Chairs : J. Cuzick - G. Ronco</b>				
	• Status of cervical cancer screening in European countries and guidelines	von Karsa	L.	France	
	• Introduction of primary HPV screening in organized screening programs	Dillner	J.	Sweden	
	• Implementation of HPV screening : national vs regional projects (organization, assessment, problems, solutions, results, communications)				
	- Netherlands	Meijer	C.	Netherlands	
	- Italy	Ronco	G.	Italy	
	- Germany	Hillemanns	P.	Germany	
	- Spain	Granado de la Orden	S.	Spain	
	- US (FDA approval)	Lawson	H.	USA	
	• Updated benefits & harms of HPV DNA screening implementation	Antilla	A.	Finland	
10:00 - 11:30	<b>MSS 6 - Roadmap 2015: Management &amp; control of HPV associated diseases - current knowledge and new horizons - a debate</b>	Auditorium 3			
	<b>Chairs : S. Franceschi - J. Monsonego</b>				
<b>TOPIC 1</b>	<b>How HPV knowledge has changed our practice: screening and management of neoplastic lesions</b>				
<b>Section 1</b>	• Cervix				
	- HPV screening				
	• in non-vaccinated women	Wentzensen	N.	USA	
	• in vaccinated women	Berkhof	H.	Netherlands	
		Canfell	K.	Australia	
	- Role of HPV in the management of abnormal Pap & CIN	Einstein	M.	USA	
		Arbyn	M.	Belgium	
<b>Section 2</b>	• Anus	Fairley	C.	Australia	
		Bower	M.	UK	
<b>Section 3</b>	• OPC	Pai	S.	USA	
		Fakhry	C.	USA	
<b>TOPIC 2</b>	<b>How HPV knowledge has changed our practice: current and future vaccines</b>				
	• State of the art of HPV vaccine	Brotherton	J.	Australia	
	• Positioning the value of the new HPV vaccine	Jit	M.	UK	
	• Utility of cervical cancer screening in the era of multivalent and therapeutic vaccines	Gravitt	P.	USA	
	• Impact of prophylactic HPV vaccine in cancers other than cervical cancer	Brisson	M.	Canada	

## FORUM HEAD &amp; NECK CANCERS

8:15 - 10:00	<b>SS I - H&amp;N HPV driven oropharyngeal cancers (OPC): the global view</b>	Auditorium 2			
	<b>Chairs : X. Castellsagué - A. Chaturvedi</b>				
	• Burden of HPV H&N cancer a new entity? An emerging epidemic?	Chaturvedi	A.	USA	
	• HPV distribution & epidemiology	Castellsagué	X.	Spain	
	• Etiology of HPV driven OPC				
	• Risk factors for HPV head and neck cancers	Gillison	M.	USA	
	• Defining risk in HPV-associated head and neck cancer	Burtness	B.	USA	
	• Natural history - carcinogenesis	Roberts	S.	UK	
	• Role of immunity	Pawlita	M.	Germany	

14:45 - 16:30	<b>SS II - H&amp;N The HPV value for detection, control and management of oropharyngeal cancers (OPC)</b>	Auditorium 2			
	<b>Chairs : C. Fakhry - S. Pai</b>				
	• Are HPV head and neck cancers preventable by screening and early detection	Fakhry	C.	USA	
	• Expected vaccination impact on HPV head and neck	D'Souza	G.	USA	
	• Diagnosis & detection	Lacau St Guily	J.	France	
	• Biomarkers in HPV+ tumors	Pawlita	M.	Germany	
	• The role of HPV status in the treatment option of HNCC	Pai	S.	USA	
	• HPV related oropharynx cancer : focus on clinical trials and the role of treatment de-intensification	Haddad	R.	USA	
	• Personalized patient counseling	Dalianis	T.	Sweden	

17:00 - 18:15	<b>SS III - H&amp;N Decision-making in management of oropharyngeal cancers (OPC)</b>	Auditorium 2			
	<b>Chairs : T. Dalianis - R. Brakenhoff</b>				
	• Treatment				
	- Non surgical	Lefebvre	J.L.	France	
	- Surgical - robotic surgery	Fakhry	C.	USA	
	• Radiosensitivity of HPV positive tumors	Lambert*	P.	USA	
	• Prognosis & impact of HPV status in recurrent/metastatic OPC	Licitra	L.	Italy	
	• Ongoing trials	Mehanna	H.	UK	
	• Decision-making in head and neck cancers	Pai	S.	USA	

18:15 - 19:15	<b>SS IV - H&amp;N controversies and key questions</b>	Auditorium 2			
	<b>Chairs : J.L. Lefebvre - H. Mehanna- J. Lacau St Guily - F. Esteban - B. Burtness</b>				
	• Oral HPV natural history	Pierce Campbell	C.	USA	

8:00 - 9:30	<b>SS 3 - FIGO session - Cervical cancer prevention in low-resource countries</b>	Madrid			
	<b>Chairs : L. Cabero-Roura</b>				
	• Worldwide epidemiology of cervical cancer: prevalence, incidence, mortality. Rates and tendencies.	De Sanjosé	S.	Spain	
	• Reality of HPV vaccination in under developed countries	LaMontagne	S.	USA	
	• Cervical cancer in Africa: an epidemic in waiting?	Fiander	A.	UK	
	• Effect of VIA screening by Primary Health workers: randomized controlled study in Mumbai, India	Shastri	S.	India	
	• FIGO educational program	Bosch	X.	Spain	

9:30 - 10:30	<b>SS 4 - Italian Session (in English) (to the memory of M. Sideri<sup>†</sup>)</b>	Madrid			
	<b>Chairs : M. Sideri<sup>†</sup> - G. Ronco - M.-T. Sandri</b>				
	• Overview and update on NTCC trial	Ronco	G.	Italy	
	• Management of HPV+ women: results of research trials	Carozzi	F.	Italy	
	• Update on the implementation of HPV primary screening in Italy	Giorgio-Rossi	P.	Italy	
	• Performance of commercially available HPV tests (from studies to clinical practice)	Sandri	M.T.	Italy	
	• Population-based frequency assessment of HPV-induced lesions in patients with borderline Pap tests in the Emilia Romagna region - the Pater study.	Costa	S.	Italy	
	• Value of RLU in the management of ASC-US pap	Origoni	M.	Italy	
	• Colposcopy in cytology negative HPV positive women	Preti	M.	Italy	
	• CINtecplus to triage cytology negative HR positive women	Cristoforoni	P.	Italy	
	• HPV vaccination in Italy, an update	Mariani	L.	Italy	

8:30 - 10:00	<b>CS 5 - Clinical decision-making for cervical diseases</b>	Bruselas			
	<b>Chairs : A. Kaufmann - J. Belinson</b>				
	• Pathognomonic signs guiding biopsy and therapy decision	Schneider	A.	Germany	
	• It is the time to change the consensus about CIN 2-3 LLETZ treatment during the first trimester ?	Siegler	E.	Israel	
	• Managing 21-24 y women with CIN	Moscicki	A.B.	USA	
	• Role of biomarkers in the management of high grade CIN	Wentzensen	N.	USA	
	• Non-invasive treatment options for CIN	Hillemanns	P.	Germany	

10:00 -	<b>SS 5 - Spanish Session (in English)</b>	Bruselas			
11:30					
	• Accreditation in colposcopy: The AEPCC's program	Dexeus	S.		
	• The per-operative sample of HPV as a marker of risk of relapse or second lesion	del Pino	M.		
	• Invasive cervical cancer quality control in Spain	Castillo	M.		
		Ibáñez	R.		
	• Robotic surgery in invasive cervical cancer	Ponce	J.		

8:30 -	<b>SS 6 - Health economical modelling for HPV induced cervical cancer prevention</b>	Paris			
10:00					
	• Cost-effectiveness of mRNA vs DNA based assays for cervical cancer screening	Myers	E.	USA	
	• Optimal screening strategies in the era of vaccination in terms of cost-effectiveness - Australia	Canfell	K	Australia	
	• Optimal screening strategies in the era of vaccination in terms of cost-effectiveness - The Netherlands	Berkhof	H.	Netherlands	
	• Optimal number of HPV vaccine doses in terms of cost-effectiveness	Brisson	M.	Canada	
	• Optimal HPV vaccine in terms of cost-effectiveness (bivalent, quadrivalent, nonavalent)	Jit	M.	UK	
	• Comparing impact of different vaccination strategies (girls-only, girls & boys, and older women catch-up)	Baussano	I.	France	

10:30 -	<b>SS 7 - Screening strategies at the extremes</b>	Paris			
11:30					
	• Cervical cancer risk in women <30y & >65y	Stoler	M.	USA	
	• Screening of women <30y	Kinney	W.	USA	
	• Screening of older women >65y	Sasieni	P.	UK	
	• Management of ASCUS/LSIL women under 30	Elfström	M.	Sweden	

14:45 -	<b>MSS 7 - New insights in cervical cancer control</b>	Auditorium 3			
16:30	<b>Chairs : J. Paavonen - S. Garland</b>				
	• Community randomized HPV vaccination trial of the best vaccination strategy	Lehtinen	M.	Finland	
	• The efficacy rates against CIN3 obtained by the quadrivalent and the bivalent vaccine Phase III trials were not identical-Why?	Paavonen	J.	Finland	
	• Screening approaches for vaccinated population: Compass trial	Canfell	K.	Australia	
	• How to integrate HPV vaccination programs and organized screening programs	Nieminen	P.	Finland	

17:00 -	<b>MSS 8 - Potential impact of the quadrivalent, bivalent and nonavalent HPV vaccines, and alternative HPV vaccination strategies</b>	Auditorium 3			
18:15	<b>Chairs : M. Brisson - M. Jit</b>				
	• Impact of cross-protection on overall vaccination effectiveness against HPV-related diseases	Berkhof	H.	Netherlands	
	• Alternative dosing schedules, WHO perspective	Henao-Restrepo	A.M.	Switzerland	
	• Effectiveness and cost-effectiveness of the candidate Nonavalent vaccine	Brisson	M.	Canada	
	• Age-specific sexual activity patterns and HPV infection control	Baussano	I.	France	
	• Effectiveness and cost-effectiveness of vaccinating Men-who-Have-Sex-with-Men	Jit	M.	UK	
	• Impact of the nonavalent vaccine on cervical screening paradigms	Canfell	K.	Australia	

14:45 -	<b>SS 8 - Cancers associated with HPV: the current picture</b>	Madrid			
16:45	<b>Chairs : S. De Sanjosé - K. Syrjänen</b>				
	• Introduction: overall picture and gaps	De Sanjosé	S.	Spain	
	• Methodological issues	Franco	E.	Canada	
	• Cervix - vagina - vulva and penis	De Sanjosé	S.	Spain	
	• Anus	Fairley	C.	Australia	
	• Head & neck	Mehanna	H.	UK	
	• Skin	Smola	S.	Germany	
	• Other cancers	Syrjänen	K.	Finland	



17:00 -	<b>SS 9 - Self-sampling at the edge of becoming routines</b>	Madrid			
18:15	<b>Chairs : M. Arbyn - N. Wentzensen</b>				
	• Accuracy of HPV testing using self-collected vaginal specimen: an updated meta-analysis	Arbyn	M.	Belgium	
	• Coverage increase by offering self-sampling kits to non-participating women	Verdoodt	F.	Belgium	
	• How to triage women being hrHPV-positive on a self-sample	Verhoef	V.	Netherlands	
	• HPV detection from urine- an alternative for self-sampling	Wentzensen	N.	USA	
	• Can self-sampling become the main strategy in an HPV-based cervical cancer screening programme?	Heideman	D.	Netherlands	

14:45 -	<b>SS 10 - Recent advances on HPV latency</b>	Bruselas			
16:30	<b>Chairs : P. Gravitt</b>				
	• ROPV models of latency and immunosuppression	Doorbar	J.	UK	
	• Canine models of latency and role (?) of vaccine in suppressing reactivation	Stanley	M.	UK	
	• HPV latency in RRP: immune control and clinical implications	Steinberg	B.	USA	
	• Evidence for latency in HIV-infected women	Gravitt	P.	USA	
	• HPV load fluctuations and duration of detectable episodes vs. duration of infection in adolescents	Brown	D.	USA	
	• HPV latency in menopausal women	Rositch	A.	USA	

17:00 -	<b>SS 11 - New insights in immunology</b>	Bruselas			
18:15	<b>Chairs : S. van der Burg - A.B. Moscicki</b>				
	• HPV immunology, genital vs oral	van der Burg	S.	Netherlands	
	• Immunology of regression vs persistence	Moscicki	A.B.	USA	
	• Immune responses to HPV prophylactic vaccines	Einstein	M.	USA	
	• Novel approaches for therapeutic vaccination of HPV-associated neoplasia	Reuschenbach	M.	Germany	
	• The role of natural immune control in the effectiveness of non-immune treatment	Kaufmann	A.	Germany	

18:15 -	<b>SS 12 - The biology of HPV: what's new</b>	Bruselas			
19:30	<b>Chairs : J. Doorbar - S. Smola</b>				
	• HPV epithelial tropisms and the site-specific development of neoplasia	Doorbar	J.	UK	
	• Epithelial target cell and the development of cervical disease; current thinking & observations	Reich	O.	Austria	
	• HR + LR protein function in Alpha HPV infections and carcinogenesis	Banks	L.	Italy	
	• Viral gene action during HPV infection - immunevasion strategies + persistence	Smola	S.	Germany	

14:45 -	<b>CS 6 - HPV infection: the state of the art</b>	Paris			
16:30	<b>Chairs : M. Goodman - E. Franco</b>				
	• Men and women epidemiology - genital vs anal & oral	Giuliano	A.	USA	
	• Immunological factors which may be common or different at oral, anal or genital sites of infection	Stern	P.	UK	
	• HPV infection in children	Syrjänen	S.	Finland	
	• Current knowledge on transmission	Goodman	M.	USA	
	• The environment of HPV	Moscicki	A.B.	USA	
	• Prevention: vaccination vs education	Romanowski	B.	Canada	

17:00 -	<b>CS 7 - Anogenital HPV infection in men</b>	Paris			
18:15	<b>Chairs : B. Lu - C. Lacey</b>				
	• Anal cancer screening - The role of digital rectal exam	Nyitray	A.	USA	
	• The utility of HR anoscopy in the management of AIN	Bower	M.	UK	
	• Epidemiology of anal HPV infection, transmission and natural history	Lu	B.	USA	
	• Management of genital warts: updated guidelines	Steben	M.	Canada	
	• The development of triage strategies for the management of AIN	Lacey	C.	UK	

Saturday, Feb. 7

8:30 - 10:00	<b>MSS9 - HPV vaccines: unexpected findings</b>	Auditorium 3			
	<b>Chairs : E. Joura - B. Romanowski</b>				
	• L2-based HPV second generation vaccines (RG1-VLP)	Schellenbacher	C.	Austria	
	• Attribution of vaccine types in mixed infection	Joura	E.	Austria	
	• HPV vaccination in immunosuppressed	Moscicki	A.B.	USA	
	• Utility of fewer doses - effectiveness	Romanowski	B.	Canada	
	• Impact of HPV 16-18 vaccination on genital warts	Soldan	K.	UK	
	• Cross-neutralising antibodies in the cross-protection against 16/18 by bivalent & quadrivalent vaccines	Paavonen	J.	Finland	

10:00 - 11:30	<b>MSS 10 - Novel approaches of HPV and non HPV-based cervical cancer screening</b>	Auditorium 3			
	<b>Chairs : P. Snijders - K. Cuschieri</b>				
	• Biomarker tests	von Knebel-Doeberitz	M.	Germany	
	• Methylation	Snijders	P.	Netherlands	
	• Genotyping	Cuzick	J.	UK	
	• mRNA	Cuschieri	K.	UK	
	• Self-sampling	Heideman	D.	Netherlands	
	• Novel approaches of HPV and non-HPV-based cervical cancer screening in developing countries	Lorincz	A.	UK	

13:00 - 14:30	<b>SS 13 - Basic molecular techniques and quality control of HPV testing</b>	Auditorium 3			
	<b>Chairs : M. Poljak - F. Carozzi</b>				
	• Quality control of HPV testing in cervical cancer screening: from the patient sample to the communication of the results	Cubie	H.	UK	
	• Commercially available HPV tests, global overview and future challenges	Poljak	M.	Slovenia	
	• Cervical cancer screening of the vaccinated cohorts	Arbyn	M.	Belgium	
	• Clinically oriented external quality assurance programmes for HPV diagnostic tests: urgent need	Carozzi	F.	Italy	
	• Internal quality control requirements and external quality assurance programs for commercial and in-house HPV genotyping tests: current status	Eklund	C.	Sweden	
	• Novel HPV types beyond HPV-150: an overview	Dillner	J.	Sweden	
	• Global genomic diversity of HPV 6 and 11	Jelen	M.	Slovenia	

8:15 -	<b>OC 12 - Screening (1)</b>	Auditorium 2		
10:00	<b>Chairs : B. Andrae - J.J. Baldauf - E. Lynge</b>			

10:00 -	<b>OC 13 - HPV Screening (2)</b>	Auditorium 2		
12:00	<b>Chairs : M. Rebolj - F. Carozzi</b>			

12:00 -	<b>OC 14 - Self-sampling</b>	Auditorium 2		
13:15	<b>Chairs : D. Heideman - J. Bonde</b>			

8:00 -	<b>SS 14 - CoHeaHr</b>	Madrid		
10:00	<b>Chairs : C. Meijer - M. Elfström</b>			
	• Overview of CoheaHr. Self-sampling for primary HPV screening	Berkhof	H.	Netherlands
	• Comparative effectiveness research in optimization of cervical cancer control	Dillner	J.	Sweden
	• HPV clearance rates: impact on cervical cancer control strategies	Ronco	G.	Italy
	• HPV transmission modelling in optimizing preventive strategies	Baussano	I.	France
	• Vaccination of mid-adult women	Bosch	X.	Spain
	• Efficacy of HPV vaccines	Arbyn	M.	Belgium
	• Effect of vaccination strategies on screening	Veldhuijzen	N.	Netherlands
	• Integration of vaccination and screening	Lehtinen	M.	Finland

10:00 -	<b>SS 15 - Prevention of cervical cancer in Central and Eastern Europe and Central Asia</b>	Madrid			
11:30	<b>Chairs : M. Poljak</b>				
	• Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia	Bray	F.	France	
	• Cervical cancer screening practices and current status of vaccination implementation in the Russian Federation	Rogovskaya	S.	Russia	
	• Cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe	Seme	K.	Slovenia	
	• Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia	Berkhof	H.	Netherlands	
	• Recommendations for cervical cancer prevention in Central and Eastern Europe and Central Asia	Poljak	M.	Slovenia	

11:30 -	<b>SS 16 - HPV infection, cervical cancer prevention in low income countries</b>	Madrid			
13:00	<b>Chairs : R. Sankaranarayanan</b>				
	• Cervical cancer prevention initiatives in China: Care HPV	Qiao	Y. L.	China	
	• Updated results from the Indian study of less than 3 doses of HPV vaccination	Sankaranarayanan	R.	France	
	• Cervical cancer prevention in HIV infected women	Smith	J.	USA	

8:30 -	<b>OC 15 - Anal neoplasia</b>	Bruselas			
10:00	<b>Chairs : J. Palefsky - A. Nyitray</b>				

10:00 -	<b>OC 16 - Vulvar, vaginal &amp; other neoplasia</b>	Bruselas			
11:30	<b>Chairs : A. Tristram - F. Borruto</b>				

11:30 -	<b>OC 17 - Molecular markers biology &amp; immunology</b>	Bruselas			
13:00	<b>Chairs : M. von Knebel Doeberitz* - C. Depuydt*</b>				

\* to be confirmed